A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The hypothesis of this study is that the p38 inhibitor (PH-797804) will be safe and well tolerated in subjects with rheumatoid arthritis who are taking methotrexate and will not effect the blood levels of methotrexate.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Methotrexate

Criteria

Inclusion Criteria:

• Adult with RA for at least 6 months

• Stable weekly dosage of oral methotrexate 12.5- 25 mg/week

Exclusion Criteria:

• Severe, progressive and/or uncontrolled other disease

• Chronic or recent serious infection; current infection

• Concomitant use of RA therapy other than methotrexate with some exceptions